- Efavirenz/emtricitabine/tenofovir, sold
under the
brand name
Atripla among others, is a fixed-dose
combination antiretroviral medication used to treat...
- efavirenz/emtricitabine/tenofovir (
Atripla),
which is
marketed by
Gilead and Bristol-Myers Squibb. HIV drug
prices have
increased substantially.
Atripla, a
combination therapy...
- Food and Drug
Administration (FDA) on July 12, 2006,
under the
brand name
Atripla.
Emtricitabine is
indicated in
combination with
other antiretroviral agents...
- needed] In July 2006, the U.S. Food and Drug
Administration (FDA)
approved Atripla, a once a day
single tablet regimen for HIV,
combining Sustiva (efavirenz)...
- not be
administered to
patients on efavirenz/emtricitabine/tenofovir (
Atripla).
Symptoms of an overdose[unreliable
medical source?] include: Coma Hypoventilation...
-
research and development.
Gilead is
known for
developing drugs such as
Atripla (for HIV/AIDS) and
commercializing Sovaldi (sofosbuvir) for the treatment...
-
Umifenovir (Arbidol)
Influenza Hemagglutinin inhibitor Atazanavir HIV PI
Atripla (Efavirenz/emtricitabine/tenofovir) HIV Efavirenz: Non-nucleoside RTI (NNRTI)...
- of
antiviral drugs into a
single dose. Well-known
combinations include Atripla (tenofovir disoproxil/emtricitabine/efavirenz),
Complera (tenofovir...
- 84% Sanofi-Aventis
Diabetes mellitus type 1 and 2 Apr-2000 Dec-2011 16
Atripla Emtricitabine/tenofovir/efavirenz 679,418 0.36%
Gilead Sciences, Inc. HIV...
-
Infectious diseases,
including HIV
infection and ****ociated
conditions Atripla (efavirenz/emtricitabine/tenofovir
disoproxil fumarate) –
comarketed with...
